Suzetrigine (Journavx): The First Non-Opioid Painkiller of a New Class in Decades

In Brief

For decades pain relief has rested on two pillars: non-steroidal anti-inflammatories, which suppress inflammation, and opioids, which act in the brain. The first have a ceiling of effect and their own price for stomach and kidneys; the second bring sedation, tolerance and dependence — the dependence that cost the United States an epidemic.

Suzetrigine is built differently. It selectively blocks the NaV1.8 sodium channel — that one out of the nine known voltage-gated sodium channels. The channel operates in peripheral sensory neurons, including dorsal root ganglion neurons, and transmits pain signals. The label describes the result this way: by inhibiting NaV1.8, the drug inhibits transmission of pain signals to the spinal cord and brain. The signal is damped where it arises, not where it is perceived.

Hence the central promise: relief without reinforcement, and therefore without addiction. The promise is logical. Let us see how much of it has been verified.

What the Trials Showed

Approval rested on two phase 3 trials, published together (Bertoch T, Anesthesiology 2025). Both models are elective surgery with predictably severe pain afterwards.

• NAVIGATE 2 — abdominoplasty, 1,118 participants.
• NAVIGATE 1 — bunion surgery on the foot, 1,073 participants.

Follow-up ran 48 hours. The comparison was against two things at once: placebo, and a live competitor — the hydrocodone/acetaminophen combination, that is, an opioid.

The first row is the headline result: the drug works, and against placebo that is shown convincingly in both operations. Note the spread between them — 48.4 and 29.3. A near-twofold difference means the size of the effect depends markedly on which surgery it was, and the figure cannot be carried from one situation to another.

What Gets Lost in Retellings

The authors put the outcome this way: pain reduction with suzetrigine was «similar» to the opioid combination. And here caution is needed in both directions. Turning this into «weaker than opioids» is wrong: no difference was found. But turning it into «proven to be no worse» is equally wrong — an absence of statistical difference does not by itself establish equivalence, which requires a different trial design and a pre-specified margin.

That is precisely the point of the published methodological critique (Mistry T, Saudi J Anaesth 2026): «Absence of statistical difference in the setting of marked heterogeneity and wide confidence intervals does not establish therapeutic equivalence.» The same letter raises two further objections to the pooled analysis of the drug's data: extremely high heterogeneity between the included studies, and the fact that only the highest-dose arms were pooled, which inflates the effect estimate.

On the Speed of Relief

The figure that most often reaches headlines: pain eased noticeably after 119 minutes versus 480 minutes on placebo. It is real, but it needs two qualifications.

First: that is the result from one of the two operations. After abdominoplasty it was 119 versus 480 minutes; after foot surgery, 240 versus 480 — twice as fast, not four times.

Second, and more importantly: the authors mark both estimates as descriptive. That did not happen by accident. In this design the endpoints are tested in sequence, and once one is not met — here, superiority over the opioid — everything after it loses confirmatory status. Formally this is an observation, not a proven result.

«No Addiction Risk»: Where It Comes From

The phrase about relief «without addiction concerns» really is in the paper. What matters is where it sits: in the background section, among descriptions of the potential the mechanism offers. It is a hypothesis, and a good one — the drug does not act in the brain, so it has nothing to reinforce behaviour with.

But the trials themselves did not measure addiction. Neither tolerance nor abuse potential were endpoints, and 48 hours of follow-up is unsuited to that question in principle. No separate abuse-potential study could be found in the publication database.

Who Paid for the Research

This is no reason to discard the result, but the reader is entitled to know. Five authors of the pivotal publication are employees of the manufacturer, holding its stock and options. Eight more received company fees as members of its acute pain steering committee. One author declared no conflict of interest.

Such a structure is typical of pivotal trials: the manufacturer is the one who runs them. But that is exactly why independent critique and subsequent comparisons carry more weight than usual.

Endometriosis: What We Do Not Know

The question arises naturally. Pain in endometriosis is severe, chronic and poorly served by the usual remedies, and a drug with a new mechanism looks like an obvious candidate.

Let us say it plainly: there are no clinical data at all. Not a single registered trial of suzetrigine in endometriosis, pelvic pain or dysmenorrhoea exists — verified both in the publication database, through ten different query formulations, and in the trials registry, where the drug has 48 studies and none on this topic.

What does exist is the target. In work on ovarian endometrioma tissue, oestrogen-activated mast cells released nerve growth factor, which sensitised dorsal root ganglion neurons by raising NaV1.8 expression (Zhu TH, Reproduction 2018). Three qualifications, without which that finding misleads:

• NaV1.8 is not alone there: the same sentence names a second channel, TRPV1, so this is a finding about neuronal sensitisation rather than about this drug's target specifically.
• What correlated with the severity of painful periods was oestrogen concentration and mast cell numbers, not channel expression.
• The work was done on tissue and cell lines in 2018, years before the drug reached the clinic; suzetrigine took no part in it.

The only trial that mentions the pelvis at all is pain relief after pelvic floor surgery — that is, acute postoperative pain again. And its criteria list chronic pain syndromes among the exclusions.

The section's bottom line: there are grounds for scientific interest, and no grounds for a patient's expectations. And it is worth remembering separately that chronic pelvic pain is not the same as endometriosis: it has other causes that are treated differently — pelvic congestion syndrome, for one.

What Comes Next

Chronic pain is already being studied, and this is the most interesting direction. In painful diabetic neuropathy three phase 3 trials are running and one phase 2 trial is complete. There are programmes in painful lumbosacral radiculopathy and in small fibre disease.

If the effect holds up in chronic neuropathic pain, the drug's significance changes in kind: today it is an alternative to an opioid for a few days after surgery; there it would be an alternative to gabapentinoids and antidepressants for months.

Safety: What the Label Says

This is a prescription drug, and its warnings section is not a formality.

• One contraindication, and it matters: strong CYP3A inhibitors. Concomitant use is prohibited because they raise exposure to the drug and its active metabolite.
• Avoid grapefruit throughout treatment, for the same reason.
• Liver. In severe hepatic impairment (Child-Pugh class C) use should be avoided; in moderate impairment (class B) the dose is lower.
• Hormonal contraception. The drug is itself a CYP3A inducer. If the contraceptive contains a progestin other than levonorgestrel or norethindrone, an additional non-hormonal method is needed during treatment and for 28 days after it.
• Common adverse reactions, more frequent than on placebo: pruritus, muscle spasms, raised creatine phosphokinase, rash.
• Pregnancy. There are no data on use in pregnancy. In rat studies, effects on implantation and maintenance of pregnancy occurred at doses from 2.2 times the maximum recommended human dose.
• How it is taken. Tablets are swallowed whole; the starting dose is taken on an empty stomach, an hour before food or two hours after, otherwise onset is delayed.

On the heart, separately: at twice the exposure of the maximum recommended dose, no clinically significant QT prolongation was observed.

The Practical Part

• It cannot be bought in Ukraine or Europe. The drug is prescription-only and sold in the US; no registration could be found in the European Union, the United Kingdom or Ukraine.
• The indication is limited to acute pain in adults. Safety and effectiveness have not been established in children.
• This is medicine for days, not for continuous use. All available efficacy data were gathered over 48 hours.
• If it is offered to you for chronic pain, that is off-label prescribing, and the conversation with your doctor should start there.

The Bottom Line

Suzetrigine is a genuine event in pain pharmacology, and the reason is not the size of the effect. The reason is that for the first time in decades pain relief has taken a fundamentally different route: not through the brain, but by switching off the signal in the nerve itself. That route has a chance of delivering what opioids cannot — relief that does not reinforce itself.

But a chance is not yet a result. Against placebo the drug works; that is shown. It did not beat the opioid, and equivalence to it was not proven either. Addiction was not measured. In chronic pain, trials are running. In endometriosis, they have not begun.

The good news is that all these gaps are being closed by studies already under way. The bad news is that until those results arrive, every promise remains a promise, however elegant the molecule.